HK Inno.N

HK Inno.N EPS

The Earnings per Share (EPS) of HK Inno.N (195940.KQ) as of Oct 27, 2026 is 2,672.08 KRW. In the previous year, Earnings per Share (EPS) was 2,173.68 KRW — a change of 22.93% (higher).

EPS

2,672.08KRW

YoY

22.93%

Last updated:

Earnings per Share (EPS) of HK Inno.N is 2025 2,672.08 KRW. Earnings per Share (EPS) of HK Inno.N was 2024 2,173.68 KRW. It decreases by 22.93% higher compared to the previous year.

The HK Inno.N EPS history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EPS
Date
EPS
Jan 1, 2021
855.78 KRW
Jan 1, 2022
1,346.08 KRW
Jan 1, 2023
1,666.05 KRW
Jan 1, 2024
2,173.68 KRW
Jan 1, 2025
2,672.08 KRW
Jan 1, 2026 (e)
3,070.68 KRW
Jan 1, 2027 (e)
3,605.92 KRW
Jan 1, 2028 (e)
4,261.49 KRW
The HK Inno.N EPS history
YEAREPSYoY
est4,261.49KRW+18.18%
est3,605.92KRW+17.43%
est3,070.68KRW+14.92%
2,672.08KRW+22.93%
2,173.68KRW+30.47%
1,666.05KRW+23.77%
1,346.08KRW+57.29%
855.78KRW-11.33%
965.13KRW+111.06%
457.28KRW-255.11%
-294.82KRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

HK Inno.N Stock analysis

What does HK Inno.N do? HK inno.N Corp. generates revenue through its Prescription Drug segment, which manufactures and sells hormone drugs, anticancer drugs, high blood pressure drugs, gastroesophageal reflux disease drugs, blood nutrient supplies, and circulatory system products. The Health Beauty and Beverage (HB&B) segment contributes by producing and distributing hangover relieving products, health drinks, and food items. The Other segment earns income from trademark royalties and additional services. Products are sold domestically and internationally, targeting healthcare consumers and businesses seeking pharmaceutical and wellness solutions. The company's Prescription Drug segment focuses on specialized medical treatments, while HB&B targets health-conscious consumers with lifestyle products. Trademark royalties in the Other segment provide supplementary revenue from intellectual property licensing. Domestic sales form a significant portion of the business, with international markets expanding the company's reach. HK inno.N Corp. serves healthcare providers and end consumers through its Prescription Drug segment, with products like anticancer and high blood pressure drugs. HB&B products such as hangover relievers and health drinks cater to individual wellness needs. The Other segment’s trademark royalties support brand value, with sales spanning both local and global markets. HK Inno.N is one of the most popular companies on Eulerpool.

Frequently Asked Questions about HK Inno.N stock

Earnings per Share (EPS) of HK Inno.N is 2,672.08 KRW in 2025.

Earnings per Share (EPS) of HK Inno.N changed from 2,173.68 KRW to 2,672.08 KRW, representing a 22.93% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Earnings per Share (EPS) HK Inno.N since 2006 – with annual values, charts, and detailed analysis.

Earnings per Share measures the portion of a company's profit allocated to each outstanding share. It is a key metric for assessing a company's profitability on a per-share basis.

EPS = Net Income / Shares Outstanding

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — HK Inno.N

All Key Metrics — HK Inno.N